International Journal of Antimicrobial Agents

(The H4-Index of International Journal of Antimicrobial Agents is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-10-01 to 2023-10-01.)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges3484
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial3192
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality1215
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?699
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence678
Coronavirus disease 2019 (COVID-19): current status and future perspectives654
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19605
The epidemiology, diagnosis and treatment of COVID-19581
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection403
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies341
Chloroquine for the 2019 novel coronavirus SARS-CoV-2298
Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status242
Arguments in favour of remdesivir for treating SARS-CoV-2 infections236
Extra-respiratory manifestations of COVID-19209
Increased antimicrobial resistance during the COVID-19 pandemic197
Teicoplanin: an alternative drug for the treatment of COVID-19?181
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking181
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies177
SARS-CoV-2 was already spreading in France in late December 2019177
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein170
Procalcitonin levels in COVID-19 patients167
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine155
Tocilizumab for severe COVID-19: a systematic review and meta-analysis129
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)122
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update114
Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment112
Ribavirin therapy for severe COVID-19: a retrospective cohort study108
Lactoferrin as potential preventative and adjunct treatment for COVID-19105
Different mutations in SARS-CoV-2 associate with severe and mild outcome101
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants94
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-1989
Drug repositioning is an alternative for the treatment of coronavirus COVID-1983
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-1980
Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients80
Azole resistance mechanisms in Aspergillus: update and recent advances79
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment78
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line78
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study78
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies76
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic75
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal75
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-1975
Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections74
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology72
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.10594971
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal71
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial65
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors61
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review59
A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections57
SARS-CoV-2: fear versus data56
Long-acting drugs and formulations for the treatment and prevention of HIV infection56
Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges55
Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemi55
Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis55